For Q4 2025, Recursion generated 35537000 in total revenue, primarily from collaboration agreements, compared to 4546000 in Q4 2024. Net loss narrowed to 108124000 from 178905000 in the prior year quarter. The company ended the quarter with 753921000 in cash, cash equivalents and restricted cash.

Recursion Pharmaceuticals posted a Q3 net loss of $162.3M amid higher R&D spend and reduced revenue from collaborations. Despite the widening loss, the company secured a $30M milestone payment and maintains a strong cash position with runway through 2027.

Recursion saw higher revenue from collaborative agreements but posted a significantly larger net loss due to increased research and development spending and expanded administrative costs following the Exscientia acquisition.

Recursion posted higher revenue but also much higher losses in Q1 2025, driven by a major jump in R&D and administrative costs due to the integration with Exscientia and expanded platform efforts.

Recursion Pharmaceuticals saw a significant revenue decline due to the timing of projects from its Roche and Genentech collaboration. Net loss increased primarily due to rising research and development expenses and administrative costs following the acquisition of Exscientia.

Recursion Pharmaceuticals reported its Q3 2024 financial results, with a focus on the anticipated closing of the business combination with Exscientia. The company highlighted multiple clinical trial milestones and an expanded collaboration with Google Cloud. Total revenue increased to $26.1 million, driven by the Roche & Genentech partnership and a $30 million acceptance fee for a neuroscience phenomap.

Recursion and Exscientia have entered into a definitive agreement to combine their businesses, aiming to create a leading technology-first, end-to-end drug discovery platform. The combined entity expects approximately 10 clinical readouts over the next 18 months and anticipates annual synergies of approximately $100 million.

Recursion Pharmaceuticals reported a revenue of $13.8 million and a net loss of $91.4 million for the first quarter of 2024. The company is on track to read out multiple Phase 2 clinical trials in the coming quarters and has completed performance benchmarking on its next-generation supercomputer, BioHive-2.

Recursion Pharmaceuticals reported a revenue of $10.9 million and a net loss of $93.0 million for the fourth quarter of 2023. The company's cash and cash equivalents totaled $391.6 million as of December 31, 2023.

Recursion Pharmaceuticals reported a revenue of $10.5 million and a net loss of $93.0 million for the third quarter of 2023. The company highlighted its collaboration with Tempus, the expansion of its supercomputer BioHive-1, and the updated collaboration with Bayer.

Recursion Pharmaceuticals reported a total revenue of $11.0 million for Q2 2023, an increase from $7.7 million in Q2 2022, driven by progress in the Roche-Genentech collaboration. The company's net loss was $76.7 million, compared to a net loss of $65.6 million for the same period in the previous year. The company's cash and cash equivalents were $405.9 million as of June 30, 2023.

Recursion Pharmaceuticals reported a revenue increase in Q1 2023, driven by progress in the Roche-Genentech collaboration. The company also advanced its clinical trials and made strategic acquisitions of Cyclica and Valence to bolster its digital chemistry and generative AI capabilities. However, the company experienced increased research and development expenses and general and administrative expenses, leading to a higher net loss compared to the same period last year.

Recursion Pharmaceuticals reported a revenue of $13.7 million for the fourth quarter of 2022, compared to $2.5 million for the fourth quarter of 2021. Net loss was $57.5 million for the fourth quarter of 2022, compared to a net loss of $64.9 million for the fourth quarter of 2021.

Recursion Pharmaceuticals reported a revenue of $13.2 million and a net loss of $60.4 million for the third quarter of 2022. The company initiated several clinical trials and nominated a new clinical program. They also completed a private placement offering, raising gross proceeds of approximately $150.3 million.

Recursion Pharmaceuticals reported a revenue of $7.7 million for the second quarter of 2022, compared to $2.5 million for the second quarter of 2021. Net loss was $65.6 million for the second quarter of 2022, compared to a net loss of $43.4 million for the second quarter of 2021. Cash, cash equivalents and investments were $515.4 million as of June 30, 2022.

Recursion Pharmaceuticals reported a net loss of $56.0 million for the first quarter of 2022, with total revenue of $5.3 million. The company highlighted progress in its clinical programs, including the enrollment of the first participant in a Phase 2 clinical trial for CCM and advancements in preclinical and discovery programs.